NeuBase Therapeutics, Inc.
NBSEDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted in 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 18
- Q1 2024, −2 vs. previous quarter
- 13F value
- $177.1K
- Reported value at the end of Q1 2024
- Superinvestors holding
- 1
- At the end of Q1 2024
Superinvestors holding NBSE, Q1 2024
1 superinvestor reports holding NeuBase Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
<0.1%
NeuBase Therapeutics, Inc.'s share of the portfolio
- Shares
- 136,350
- Value
- $61.3K
Latest insider trades
Open-market purchases and sales by NeuBase Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2023 (view filing) | Sep 14-18 | 4 days | Symetryx Corp10% Owner | SSaleCommon Stock, Par Value $0.0001 per Share | −282.4K | $1.33 | −$375.6K | −100.0%0 after | 3 lots |
| Sep 11, 2023 (view filing) | Sep 7-11 | 4 days | Symetryx Corp10% Owner | SSaleCommon Stock, Par Value $0.0001 per Share | −207.1K | $1.63 | −$336.7K | −30.5%472.9K after | 3 lots |
| Sep 7, 2023 (view filing) | Sep 1 | 6 daysLate | Symetryx Corp10% Owner | PPurchaseCommon Stock, Par Value $0.0001 per Share | +61.1K | $0.98 | +$59.9K | +9.9%680.1K after | |
| Apr 1, 2022 (view filing) | Mar 30 | 2 days | Mann William RolandChief Operating Officer | PPurchase | +6.20K | $1.92 | +$11.9K | +124.0%11.2K after | |
| Mar 21, 2022 (view filing) | Mar 18 | 3 days | Branning Todd P.Chief Financial Officer | PPurchase | +10.0K | $1.81 | +$18.1K | +50.0%30.0K after | |
| Mar 18, 2022 (view filing) | Mar 16-17 | 2 days | Branning Todd P.Chief Financial Officer | PPurchase | +20.0K | $1.68 | +$33.6K | New position20.0K after | 2 lots |
| Mar 7, 2022 (view filing) | Mar 1-4 | 6 daysLate | Richman Eric IDirector | PPurchase | +3.88K | $1.64 | +$6.35K | +9.4%45.0K after | 3 lots |
Top 10 13F holders, Q1 2024
The largest institutional positions in NeuBase Therapeutics, Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 136,350 | $61.3K | 0.00% | +136,350 | New |
| Renaissance Technologies LLC | 88,229 | $40.0K | 0.00% | +31,262+54.9% | Added |
| Point72 Asset Management, L.P. | 62,500 | $28.1K | 0.00% | 00.0% | Unchanged |
| Carnegie Mellon University | 46,970 | $21.1K | 0.03% | 00.0% | Unchanged |
| Vanguard Group Inc | 18,981 | $8.54K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 15,550 | $7.00K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 15,482 | $6.84K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,056 | $1.82K | 0.00% | −61,668−93.8% | Reduced |
| Tower Research Capital LLC (TRC) | 2,572 | $1.16K | 0.00% | +124+5.1% | Added |
| Cubist Systematic Strategies, LLC | 1,251 | $563 | 0.00% | +1,251 | New |